Ads
related to: bisphosphonate and bone loss
Search results
Results From The WOW.Com Content Network
Bisphosphonates have been used to reduce fracture rates in children with the disease osteogenesis imperfecta [24] and to treat otosclerosis [25] by minimizing bone loss. Other bisphosphonates, including medronate (R 1 =H, R 2 =H) and oxidronate (R 1 =H, R 2 =OH), are mixed with radioactive technetium and injected, as a way to image bone and ...
Chemical structure of bisphosphonates. Bisphosphonates are an important class of drugs originally commercialised in the mid to late 20th century. They are used for the treatment of osteoporosis and other bone disorders that cause bone fragility and diseases where bone resorption is excessive.
Owing to prolonged embedding of bisphosphonate drugs in the bone tissues, the risk for BRONJ is high even after stopping the administration of the medication for several years. [18] [19] This form of therapy has been shown to prevent loss of bone mineral density (BMD) as a result of a reduction in bone turnover.
Osteoporosis can affect nearly 1 in 3 women and the bone loss is the most rapid within the first 2–3 years after menopause. This can be prevented by menopause hormone therapy or MHT, which is meant to prevent bone loss and the degradation of the bone microarchitecture and is noted to reduce the risk of fractures in bones by 20-30%.
Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. [4] It is taken by mouth. [4] Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes. [4]
Etidronic acid is a bisphosphonate used to strengthen bone, treat osteoporosis, and treat Paget's disease of bone.. Bisphosphonates primarily reduce osteoclastic activity, which prevents bone resorption, and thus moves the bone resorption/formation equilibrium toward the formation side and hence makes bone stronger on the long run.
The results suggest that bone loss could be an effect of levothyroxine use in older adults, even when used at the appropriate dosage, which could be a concern in terms of osteoporosis risk.
Bisphosphonates are drugs that are used to prevent bone mass loss and are often used to treat osteolytic lesions. Zoledronic acid (Reclast) is a specific drug given to cancer patients to prevent the worsening of bone lesions and has been reported to have anti-tumor effects as well. [5]